Company stands out in Ethics, Environment, and Labor and Human Rights focus areas for 2024 pls logo Pace Life Sciences logo ...

CHICAGO, IL AND ERIE, PA / ACCESS Newswire / April 1, 2025 / Aviva Aesthetics is proud to announce its latest partnership with iAesthetic Medspa, a premier medical aesthetics practice in Erie, ...

How Technology is Reshaping Aesthetic Medicine and Expanding Patient Options NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / The field of cosmetic medicine is evolving at an unprecedented pace, ...

ORLANDO, FL / ACCESS Newswire / April 1, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is ...

Pharmaceutical Market Size & TrendsGlobal size of the pharmaceutical market was at USD 1,645.75 billion in 2024 and is ...

Investment/MiscellaneousM1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment01-Apr-2025 / 17:13 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of ...

Four Industry Veterans Unite to Replace Single-Use Plastics with High-Performance Pulp Products DAYTON, OHIO / ACCESS Newswire / April 1, 2025 / PulpFixin, a groundbreaking company dedicated to ...

Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...

CDMO, has appointed Dr James Miskin as Non-Executive Director. James brings extensive experience in the cell and gene therapy sector, following a 23-year tenure at Oxford Biomedica. He oversaw ...

Flexible PBM implements an AI-powered platform to reduce specialty drug costs while improving patient care. MILWAUKEE, WISCONSIN / ACCESS Newswire / April 1, 2025 / Serve You Rx, a full-service ...

SALT LAKE CITY, UTAH / ACCESS Newswire / April 1, 2025 / CenExel, a leading clinical research site network, has launched a new mobile application designed to make it easier for patients to find and ...

Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical ...